The diffuse sclerosing variant of papillary thyroid cancer (DSV-PTC) is a rare variant of papillary thyroid cancer (PTC) with different clinicopathological features compared with conventional PTC.
T he diffuse sclerosing variant of papillary thyroid cancer (DSV-PTC) is a rare variant of papillary thyroid cancer (PTC) with a prevalence varying from 0.3% to 5.3% (1, 2) . The DSV-PTC was described for the first time by Vickery and colleagues in 1985 (3) and it shows different clinicopathological features compared with conventional PTC. In fact, the histological features of DSV-PTC are diffuse involvement of one or both thyroid lobes, several micropapillary formations located within cleftlike spaces consistent with lymphatic vessels, extensive squamous metaplasia, large number of psammoma bodies, marked lymphocytic infiltration, and prominent fibrosis. Moreover, patients with DSV-PTC have younger age, extensive lymph node metastases, lung metastases, and more frequent local recurrence compared with conventional PTC (1).
Clinically, DSV-PTC presents with a global enlargement of thyroid gland without distinct nodular lesions associated usually with high titers of antithyroglobulin antibodies (TgAb) (4) . Due to these features, DSV-PTC may be confused with thyroiditis and this could lead to a delay in the diagnosis. The molecular features of DSV-PTC are largely unknown. A few DSV-PTC cases harboring RET/PTC rearrangement or BRAFV600E mutation have been described (5, 6) . We report here an unusual case of DSV-PTC with a KIF5B/RET rearrangement variant 1. In particular, we discuss the possibility that this thyroid tumoral tissue was indeed either a metastasis of a lung adenocarcinoma, as suggested by the presence of this specific RET rearrangement, or a case of a concomitant presence of a DSV-PTC and metastases of a lung adenocarcinoma in the same thyroid gland, as suggested by the simultaneous presence of tumoral areas either positive or negative for thyroglobulin (Tg).
Index Case
A 39-year-old man was referred to the Endocrine Oncology Unit of the Department of Clinical and Experimental Medicine of the University Hospital of Pisa in December 2013 with the histological diagnosis of DSV-PTC to perform radioiodine (RAI) treatment.
Four months before (August 2013), the patient, due to neck enlargement, was subjected to a neck ultrasound that showed a diffusely irregular hypoechoic thyroid without clear nodules associated to multiple, bilateral, latero-cervical lymph node metastases. Considering the absence of well defined thyroid nodules, a "random" fine-needle aspiration was performed in the context of the thyroid and in one of the enlarged latero-cervical lymph nodes. The cytological report was suspicious for PTC.
The patient was submitted to total thyroidectomy and bilateral latero-cervical and central compartment lymph node dissection in November 2013. The histological diagnosis was DSV-PTC with involvement of the entire thyroid gland, perithyroid soft tissue invasion, diffuse vascular and lymphatic embolization [ Fig. 1(a1-a2) in the index case, 1(a4-a5) in another DSV-PTC], marked cellular atypia [ Fig. 1(a3) in the index case, 1(a6) in another DSV-PTC], and 55 metastatic lymph nodes out of 55 lymph nodes removed (pT4amN1bMx according to the seventh American Joint Committee on Cancer's tumor-node-metastasis staging system) (7) .
One month after the surgical treatment, at the time of the evaluation for RAI treatment, neck ultrasound showed new multiple bilateral latero-cervical lymph node metastases. A computerized tomography (CT) scan showed multiple, bilateral, latero-cervical, and supraclavicular cystic lesions suspicious for lymph node metastases [ Fig.  2(a) ]. In addition, the CT scan documented multiple mediastinum lymph node metastases [ Fig. 2(b) ], the thrombosis of the left internal jugular vein, a minimal pericardial effusion, and a spiculated centimetric lesion of the upper lobe of the left lung [ Fig. 2(c) ] very suspicious to be a lung adenocarcinoma. Furthermore, the brain CT and magnetic resonance imaging scans showed multiple bilateral lesions of the cerebellum, highly suspicious for metastases ( Fig. 2(d) ].
Serum Tg and TgAb under L-thyroxine were undetectable, and serum Tg after stimulation with recombinant human thyrotropin was only slightly detectable (i.e., 0.12 ng/mL). Due to the presence of multiple lymph node metastases, the patient was submitted to RAI. The whole body scan after the administration of 3.7 GBq (100 mCi) of 131 I showed only an uptake in the central neck suggestive of thyroid remnant, but none of the other lesions were 131 I avid. Ten days after RAI, the patient was hospitalized for severe dyspnea and submitted to tracheostomy and pericardiocentesis due to massive pericardial effusion. After 1 month, he died in badly health conditions with no time to perform any additional examination or biopsy.
Considering the aggressive and unusual presentation, the negative posttherapeutic whole body scan, despite the presence of multiple diffuse metastatic lesions (lymph nodes, lung, and cerebellum), the undetectable serum Tg in the absence of TgAb (typically positive in the DSV-PTC), and the presence of a suspicious lung carcinoma, we suspected a different origin of the thyroid tumor and we asked our pathologists to review the slides of the primary and metastatic resected tumor and to perform some molecular analysis.
The revision of the histological slides confirmed that morphologically this was a DSV-PTC ( . The immunohistochemistry for CK7, which is an epithelial marker expressed both in thyroid and in lung carcinoma (8) , was positive in all areas as expected [ Fig. 1(b5) and 1(b6) ]. The immunohistochemistry for Napsin A, which is a sensitive and specific marker for lung adenocarcinoma (9, 10) , was positive in all analyzed areas [ Fig. 1(b7) and 1(b8) ].
To better clarify the origin of the thyroid tumoral tissue, we also performed an mRNA expression analysis of the thyroid differentiation markers (i.e., Tg, thyroperoxidase, and sodium-iodide symporter) in the tumoral tissue of our index case, in another case of lung adenocarcinoma, in another DSV-PTC, and in a normal thyroid tissue [ Fig. 1(c) ]. No mRNA expression of the three markers was observed in both our index case and in the lung adenocarcinoma, whereas they were clearly expressed in the normal thyroid and to a lesser extent in the other DSV-PTC.
The molecular analysis performed in the primary tumor of the index case was negative for the majority of oncogenes involved in thyroid tumorigenesis, such as BRAFV600E, RAS, and TERT mutations, as well as for RET/PTC rearrangements. At variance, looking for lung oncogenic alterations, the thyroid tumoral tissue resulted to be positive for a KIF5B/RET rearrangement variant 1 and negative for all the other oncogenes involved in lung carcinogenesis, such as EGFR and KRAS mutations and EML4/ALK rearrangement.
After this finding, we studied other 18 cases of DSV-PTC for the presence of KIF5B/RET rearrangement, but all of them were negative.
Materials and Methods
Mutational testing for BRAF, H, N, and K-Ras and TERT was performed according to previous reported procedures (11, 12) after genomic DNA extraction from serial 10 mm-thick tissue sections of paraffin blocks of the primary tumor. The KIF5B/ RET and RET/PTC1 and 3 rearrangements have been evaluated by real time reverse transcription polymerase chain reaction and direct sequencing as previously reported (13) .
The thyroid differentiation genes (Tg, thyroperoxidase, and sodium-iodide symporter) have been evaluated by real time reverse transcription polymerase chain reaction following methods previously reported (14) . Immunohistochemistry for (b) Different immunohistochemistry patterns for Tg, TTF-1, CK7, and Napsin A (3100) of two areas of tumor tissue of the IC. In the same area, we observed a strong positivity for Tg (b1), a weak positivity for TTF-1 (b3), and a strong positivity for both CK7 (b5) and Napsin A (b7): this pattern could be compatible with the DSV-PTC histology, although the positivity for Napsin A is difficult to explain. In another area, we observed a negative result for Tg (b2), a weak positivity for TTF-1 (b4), and a strong positivity for both CK7 (b6) and Napsin A (b8): this pattern could be compatible with the hypothesis that this was a metastasis of lung adenocarcinoma. (c) mRNA expression in the thyroid tissue of the IC, in another case of lung adenocarcinoma (LAd), in another case of DSV-PTC (PTC), and in normal thyroid (NT). The pattern of mRNA expression in IC is more similar to that of LAd than to those of PTC and NT. mRNA, messenger RNA.
TTF-1, Tg, Napsin A, and CK7 was performed by using commercial antibodies and following the manufacturer's procedures (Ventana Medical System) (9, 14, 15) .
According to the hospital rules, all patients sign an informed consent to the use of their clinical data and biological specimens for research purposes. The study and its ethic was approved by the internal review board.
Discussion
The DSV-PTC is a very rare histological finding. We looked at our series of PTC from 2004 to 2014 and we found only 18 cases of DSV-PTC with a prevalence of 0.3%, comparable with that of other published series (1, 2) . This variant has some peculiar features, such as the young age of the patients, the advanced stage at diagnosis, the positivity of serum TgAb, and the diffuse lymphocytic infiltration of the thyroid tissue (1) . The clinical and pathological features of the 18 cases reviewed in our series were in line with the above mentioned DSV-PTC peculiarities. It is worth to note that, despite the aggressive behavior, all the 18 patients are still alive after a median follow-up of 8 years.
The interest of the case described in the present paper is that, despite it had morphological features of a DSV-PTC, confirmed by our pathologists, the clinical behavior and in particular the rapidity of death, the absence of serum TgAb and the relatively older age of the patient were not typical of the DSV-PTC, thus arising the possibility that this was not a thyroid tumor.
Thyroid metastases, although rare, may be the first manifestation of a tumor originating in another organ. The most frequent primary sites are kidney, lung, breast, and to a lesser extent colon (16) . Although the morphology should be well recognizable in the majority of cases, sometimes the diagnosis is not so easy, and the molecular hallmarks of tumors can be useful in distinguishing the primary site of the disease (17) . In our case, a rare genetic alteration, KIF5B/RET variant 1, was the only molecular signature found in the patient's thyroid tumor. This rearrangement, described for the first time in 2012 by a Korean group (18) , was identified in a young, nonsmoker man with lung adenocarcinoma negative for EGFR, KRAS, and EML4/ALK genetic alterations. The fusion of KIF5B and RET proto-oncogene is the result of a pericentric inversion on chromosome 10, which leads to the formation of the KIF5B/RET fusion oncogene (18) . At least 13 variants of this rearrangement involving different introns of KIF5B and RET have been reported up to now (19, 20) . These rearrangements have a low prevalence (1% to 2%) in the so called "triplemarker" (EGFR, KRAS, and EML4-ALK) negative lung adenocarcinomas (18, (20) (21) (22) (23) , but the clinical significance of this rearrangement is not completely elucidated.
BRAFV600E, RAS point mutations, and RET/PTC rearrangements have been demonstrated to be the most frequent alterations in differentiated thyroid cancer. In particular, BRAFV600E and RET/PTC rearrangements are almost peculiar of PTC, whereas RAS is more frequent in follicular thyroid cancer (24) . None of these mutations were found in our index case. To our knowledge, only two reports about specific molecular signature of DSV-PTC have been reported showing a low prevalence of BRAFV600E mutation (20%) and a higher prevalence (59%) of RET/PTC rearrangements, with 43% of RET/PTC1 and 16% of RET/PTC3 (5, 6). At variance, the KIF5B/RET has never been reported neither in PTC nor in other more aggressive thyroid tumors even when studies were performed with advanced molecular analysis techniques and big series (24, 25) .
Because TERT promoter mutation is considered a poor prognostic factor and usually correlates with the aggressiveness of thyroid tumors and a short survival, the index case, whose carcinoma was aggressive and lethal, was also studied for this mutation that resulted to be negative (26) . However, the prevalence of TERT promoter mutation is rather rare also in lung adenocarcinoma and its absence cannot be helpful in distinguishing the two histological types. Similarly, the negativity of RAS mutations did not add any information about the possible origin of the tumor because it is frequent in follicular thyroid cancer but rare in PTC (27) .
According to these molecular findings (i.e., positivity of KIF5B/RET rearrangement and negativity of BRAFV600E, RAS, and TERT mutations, as well as RET/PTC rearrangements), we were reasonably convinced that this was a massive thyroid metastasis of a lung adenocarcinoma. This hypothesis can be supported also by other findings similar to ours although regarding a different primary tumor. We are referring to the case of a primary mammary analog secretory carcinoma of the thyroid masquerading as PTC with diffuse sclerosing variant that was recognized as a breast carcinoma for the presence of an ETV6-NTRK3 fusion that, up to now, has been described only in mammary analog secretory carcinoma (28) . One can argue that a second pathological revision of our case confirmed that this was morphologically a DSV-PTC, but it is also known that the KIF5B/RET rearrangement positive lung adenocarcinoma, particularly those with the variant 1, have a dominant papillarylike structure (19) that can likely mime a DSV-PTC, especially when located in the thyroid.
Other than for the presence of the KIF5B/RET rearrangement, the hypothesis that this was a case of lung adenocarcinoma with a papillarylike structure metastasized to thyroid is also supported by our results regarding the mRNA expression of the thyroid differentiation markers. In fact, they were all negative in our index case, as well as in the other lung adenocarcinoma analyzed, while they would be expected to be positive to confirm the thyroid origin.
However, the results of the immunohistochemistry and in particular the positivity and negativity of Tg in different areas of the thyroid tumoral tissue can arise a second hypothesis that the thyroid tumoral tissue analyzed could derive from the fusion of a primary DSV-PTC with a metastasis of lung adenocarcinoma. Nevertheless, the positivity of Napsin A in both areas is difficult to be explained with this hypothesis when considering that it is positive only in 5% of PTC (9) but in up to 91% of lung adenocarcinoma (10) .
In conclusion, this is a case of PTC positive for KIF5B/ RET rearrangement but, taking into consideration that this alteration has been described only in lung adenocarcinoma and that the clinical course was more typical of lung carcinoma than DSV-PTC, we are reasonably convinced that this was a metastatic lesion from a lung tumor mimicking a sclerosing variant of PTC. The absence of KIF5B/RET rearrangement in both our other 18 DSV-PTC and big series of PTC analyzed with advanced sequencing methods is also in favor of this hypothesis. The only alternative hypothesis might be that this was a case of fusion of two tumoral tissues deriving from a DSV-PTC and metastases of a KIF5B/RET positive lung adenocarcinoma. The question of whether the molecular findings, particularly when specifically reported only in some subtypes of human tumors, can overcome the morphological diagnosis is nowadays a matter of discussion.
